Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

@article{Hoffmann1994EfficacyO2,
  title={Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.},
  author={Joyce A Hoffmann and Marianne Spengler},
  journal={Diabetes care},
  year={1994},
  volume={17 6},
  pages={
          561-6
        }
}
OBJECTIVE To compare the different therapeutic principles of alpha-glucosidase inhibitors and sulphonylureas as first-line treatment in non-insulin-dependent diabetes mellitus (NIDDM) patients with dietary failure. RESEARCH DESIGN AND METHODS Ninety-six NIDDM patients (35-70 years of age, body mass index [BMI] < or = 35), insufficiently treated with diet alone (HbA1c 7-9%) were randomized into three groups and treated for 24 weeks with acarbose, glibenclamide, or placebo. Efficacy, based on… CONTINUE READING
Highly Cited
This paper has 32 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Natural products for type II diabetes treatment.

Advances in applied microbiology • 2010
View 3 Excerpts
Highly Influenced

Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas • 2002
View 4 Excerpts
Highly Influenced

Monotherapy in Patients with Type 2 Diabetes Mellitus

Diabetes & metabolism journal • 2017
View 1 Excerpt

Monotherapy in patients with type 2 diabetes mellitus

The Korean journal of internal medicine • 2017
View 1 Excerpt